The first stage of human trials of a possible vaccine for the Corona virus, developed by scientists at the University of Oxford, showed promising results, according to a report from the Daily Telegraph newspaper.
The newspaper reported that the vaccine generated an immune response in healthy volunteers during the phase that started in April.
Blood samples from healthy volunteers showed that the vaccine stimulates the body to produce antibodies and T Cells.
The head of the research ethics committee at Berkshire, David Carpenter, who agreed to the Oxford experiment, told the newspaper that the vaccine could be available during September.
The newspaper quoted an unnamed source as saying that the results did not prove that the vaccine may provide long-term immunity, but it is a vaccine that works on two sides: the production of antibodies and T cells that play a vital role in the body's immunity.
If the results are confirmed, then this potential vaccine is the only one in the world currently providing this type of double protection.
According to the source, the combination of the two can keep people safe.
The Oxford vaccine is being tested in several countries that have become foci of the spread of corona in addition to Britain, where it is being tested in Italy and Brazil, and a number of African countries.
The newspaper said that the pharmaceutical company «AstraZenka» had reached an agreement with the European Alliance for Vaccines (IVA) to supply 400 million doses of the Oxford vaccine free of charge, when the deliveries begin by the end of 2020.
The University of Oxford says that the Corona vaccine has proven effective in a laboratory environment after testing on monkeys, as it has proven to be a safe vaccine, which made European countries supportive of the vaccine, especially as its results gave optimism to everyone.